Source comparison
DSIP vs Epithalon: Research Peptide Comparison
Primary Mechanism GABA-A receptor modulation; ACTH/cortisol suppression; delta wave sleep regulation Telomerase activation; telomere elongation; circadian gene expression via pineal signaling Non-overlapping pathways. DSIP is neuroendocrine; Epithalon is epige
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GABA-A receptor modulation; ACTH/cortisol suppression; delta wave sleep regulation
- Telomerase activation; telomere elongation; circadian gene expression via pineal signaling
- Non-overlapping pathways. DSIP is neuroendocrine; Epithalon is epigenetic
- Half-Life
- 15–30 minutes in circulation
- 30–45 minutes in circulation
- Both require repeat dosing; Epithalon's longer half-life allows less frequent administration in chronic protocols
- Time to Observable Effect
- 1–3 hours (acute sleep architecture changes)
- 10–20 days (measurable telomere length changes)
- DSIP = acute intervention; Epithalon = chronic study design
- Post-Reconstitution Stability
- 7–10 days at 2–8°C (highly unstable)
- 28 days at 2–8°C (moderately stable)
- DSIP requires small-batch reconstitution; Epithalon allows standard 28-day use window
- Typical Research Dosing
- 1–10 mcg/kg subcutaneous (animal); 25–100 mcg total (human trials)
- 5–10 mg total daily for 10–20 days (human/animal)
- Epithalon dosing is 100–500× higher by mass due to different potency and mechanism
- Bottom Line
- Best suited for circadian rhythm, stress response, and acute sleep studies requiring rapid neuroendocrine shifts
- Best suited for aging research, telomere biology, and long-term cellular maintenance studies
- DSIP and Epithalon address fundamentally different biological questions. Selecting the wrong peptide wastes the entire study design